secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001558370-25-011473
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Q2 net loss $15.8M, cash $121.6M; pipeline progress on vilastobart and masked T cell engagers
--------------------------------------------------------------------------------

- Net loss $15.8M in Q2 2025 vs $13.9M a year ago; cash and equivalents $121.6M vs $55.3M at Dec 31, 2024.
- Vilastobart Phase 2 data at ASCO: 26% objective response rate in heavily pre-treated MSS CRC patients without liver metastases.
- On track to nominate first development candidates for masked T cell engagers (PSMA, CLDN18.2, STEAP1) in H2 2025.
- June 2025 follow-on offering raised ~$50M gross; up to $100M additional from warrants if exercised at $0.75 per share.
- Cash runway expected through end of Q3 2026 based on current plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025011473/0001558370-25-011473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025011473/xlo-20250814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer